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Abstract  
 
  Genome-wide association studies (GWAS) have proven to be a highly useful design in revealing the 
genetic basis of complex diseases, for example in cardiovascular medicine. At present, most of the GWAS are 
studies of a particular single disease diagnosis (e.g., coronary heart disease, asthma etc.) against controls. 
However, in clinical practice, an individual often has more than one condition/disorder. For example, patients 
with coronary artery disease (CAD) are often comorbid with diabetes mellitus (DM). Along a similar line, it is 
often clinically meaningful to study patients with one disease but without a comorbid condition. For example, 
patients with both DM and obesity may have different pathophysiology from those with DM but normal 
weight. From another angle, there may exist different ‘subtypes’ of a disease, as characterized by the absence 
or presence of comorbid conditions or disorders.   
 
   In this study, we developed a statistical framework to uncover susceptibility variants for comorbid 
disorders (or a disorder without comorbidity), which requires GWAS summary statistics only. In essence, we 
are mimicking a case-control GWAS in which the cases are affected with comorbidities or a particular disease 
but without a relevant comorbid condition (in either case, we may consider the cases as those affected by a 
specific ‘subtype’ of disease as characterized by the presence or absence of comorbid conditions). We also 
extended our methodology to deal with continuous traits with clinically meaningful categories (e.g. lipid 
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levels). In addition, we illustrated how the analytic framework may be extended to more than two 
traits/disorders. We verified the feasibility and validity of our method by applying it to simulated scenarios 
and four cardiometabolic traits. 
 
   Our proposed framework performed well in revealing susceptibility variants for comorbidities as well as 
only single trait without comorbid conditions in all simulated scenarios. Application to cardiometabolic traits 
further verified the validity of our method in unlocking the underlying susceptibility loci for cardiometabolic 
diseases ‘subtypes’.  We also analyzed the genes, pathways, cell-types/tissues involved in these disease 
subtypes. LD-score regression analysis revealed some of these ‘subtypes’ may indeed be biologically distinct 
with low genetic correlation. Further Mendelian randomization analysis also found different causal effects of 
different subtypes to relevant complications. Taken together, the proposed methodology is useful in 
uncovering the genetic basis of disease ‘subtypes’, as characterized by the presence or absence of 
comorbidities. The findings are of both scientific and clinical value, and the proposed method may open a new 
avenue to analyzing GWAS data.  
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Introduction 
 
     Genome-wide association studies have proven to be a highly useful design in revealing the genetic basis of 
many complex diseases, and has contributed to the understanding of the mechanisms of many diseases, for 
example in cardiovascular medicine and psychiatry1,2 . GWAS data also have the potential to be directly 
translated to clinical practice, for example in risk prediction by polygenic scores, disease subtyping and drug 
discovery3-8 . 
 
     To date, more than 4000 GWAS have been conducted to date (https://www.ebi.ac.uk/gwas/), and the 
emergence of large biobanks (such as the UK Biobank) has further boosted the variety and amount of 
genomic data available. Most of the GWAS (or human sequencing studies) are studies of a particular single 
disease (e.g. schizophrenia, coronary heart disease, asthma etc.) against controls.  However, in clinical 
practice, an individual patient often has more than one condition/disorder. For example, patients with 
coronary artery disease (CAD) are often comorbid with diabetes mellitus (DM), while DM patients often have 
obesity; in psychiatry, patients with schizophrenia have a higher probability of having comorbid substance 
abuse, depression, obsessive compulsive disorder and many other psychiatric disorders9.  
 
    Patients with both DM and CAD, for example, might share different pathophysiology than patients with 
DM alone or CAD alone. Viewed in another way, patients with both DM and CAD may be considered a 
‘distinct’ entity, and its etiology and genetic basis may warrant further investigations. Ideally, we would 
perform a GWAS with ‘cases’ defined as patients having both disorders, and compared their genotypes with 
control subjects. However, recruiting patients with both disorders is usually more costly than recruiting those 
with a single disorder. 
 
Along a similar line, it is often clinically meaningful to study patients with one disease but without a 
comorbid condition. For example, more than 90% of DM patients are overweight10 ;  however there are still 
DM subjects with normal weight, who may represent a specific subtype of DM. In the ideal case, we will wish 
to recruit patients with DM but normal weight as ‘cases’ and compare them against controls. However, the 
complexity and cost of recruitment is then increased (compared to the standard design of DM vs controls), 
hence limiting the practicality of such studies.  As another example, it was estimated that ~75% of patients 
with depression also suffer from anxiety disorders11; however, the rest of the patients having depression but 
no anxiety disorders may represent a specific ‘subtype’ of depression. By studying the genetic basis of such 
subgroup of patients, we will be able gain deeper understanding into the heterogeneity and pathophysiology of 
depression.  
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As raised in the above examples, many diseases are highly heterogeneous. Patients with the same 
diagnosis may have different clinical presentations and prognosis, and share different etiologies. Through 
stratifying patients of the same diagnosis by the presence or absence of comorbid condition(s) and uncovering 
the genetic basis for each subgroup, we may gain better insight into the pathophysiology of the disorder. This 
will ultimately lead to more targeted interventions or prevention strategies for distinct subgroups of patients 
with the same diagnosis.   
 
The aim of this study is to develop a framework to decipher the genetic architecture of multiple diseases in 
combination. Specifically, we wish to uncover susceptibility variants for comorbid conditions, and for 
‘subtype’ of a disease without comorbid condition(s) (e.g. DM without obesity/overweight, depression 
without anxiety, CAD without hyperlipidemia etc.). The framework can be potentially applied to any complex 
diseases, and only summary statistics are required, which greatly extends the applicability of the methodology. 
In essence, we are ‘mimicking’ a case-control GWAS in which cases are affected with comorbidities, or 
affected by a particular disease but without a relevant comorbid condition (in either case, we may consider 
cases as having a ‘subtype’ of the disease as characterized by the presence or absence of comorbidities).  
 
We will then apply such methods to cardiovascular disorders (CVD), uncover genes and pathways 
associated, and find out casual clinical risk factors for comorbid diseases (or disease without comorbidity). 
This study is mainly focused on applications in cardiovascular medicine in view of its high public health 
importance12 and that many CVD are related to each other; nevertheless, the method itself is widely 
applicable to any complex traits. The presented computational framework can be considered an extension of 
the method by Nieuwboer et al.13, for which the main focus was on finding susceptibility variants for 
functions of quantitative phenotypes such as body mass index (= weight/height2). Here we modified and 
further developed the approach to accommodate binary outcomes, which are more commonly studied in 
GWAS, and proposed new applications in deciphering the genetic basis of comorbid disorders and disease 
subtypes as characterized by the presence (or absence) of a related trait. In addition, we also developed new 
methods to handle clinically defined categories of quantitative traits, approaches to compute covariance 
between phenotypes (which are required as input) as well as more general extensions to more than two 
diseases/traits.  
 
     Here we highlight a few related directions of research. One related research area is the finding of genetic 
correlation between complex traits. LD score regression (LDSR) is a commonly used technique to compute 
genetic correlation between traits, although there are also limitations to this approach, for example there are 
inherent assumptions that may not be fully fulfilled in practice. For example it assumes that distribution of 
causal variants in the genome is independent of the LD structure, and that (ideally) the variance explained by 
each SNP is the same. Also, if the SNP effect sizes are not normally distributed, the procedure may become 
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less efficient, resulting in lower power to detect true associations14 . Another related approach is to construct 
polygenic risk scores (PRS) for the first trait, and then test associations with the second. This approach 
however cannot easily accommodate sample overlap. There is a fundamental difference between LDSR or 
PRS with the approach presented here. LDSR/PRS aims to discover overall genetic correlation or overlap 
between disorders, but are not designed for finding specific susceptibility variants underlying comorbid 
disorders or a disorder without comorbid condition(s).  
 
Another intuitive approach is to find variants passing a significance threshold (e.g. p<5e-8) for each trait, 
and directly find the overlapping variants. However, the setting of the significance threshold could be 
arbitrary, as setting a very stringent threshold (such as the conventional genome-wide significance cut-off) 
will lead to low power and carried the risk of missing genuine genetic variants contributing to comorbidity; 
setting a relaxed threshold (e.g. p<0.05) will result in increased false positive rates.  Another approach to 
develop more formal statistical procedures to find shared genetic loci. For example, a co-localization approach 
based on summary statistics was proposed in Giambartolomei’s paper15. The approach is Bayesian and 
outputs posterior probabilities that the variant is a genuine association signal for both traits. A limitation is 
that prior probabilities for different configurations of associations need to be specified, which may not be 
straightforward; difficulties may also arise for multiple independent associations at one locus. However, there 
are also fundamental differences between the ‘co-localization’ approach and our methodology. Our 
methodology can be conceptualized as mimicking the GWAS of a case-control study in which the cases are 
affected with comorbid disorders (or disease without a comorbid trait); as such, we are able to derive effect 
sizes [e.g. odds ratios(OR)] of individual genetic variants. We may conclude, for example, the allele A 
(compared to a) of a certain SNP confers an OR of 2.0 to comorbid depression and anxiety. On the other hand, 
we cannot derive effect sizes with the co-localization approach. Also, the presented method is based on the 
frequentist approach with p-values as measures of significance, which may appear more familiar to many 
biologists and clinicians. Since most GWAS analytic tools are developed based on frequentist methods or use 
p-values as input, it might be easier to perform secondary analysis (such as gene- and pathway-based analysis) 
with our methodology. 
  
    GWAS meta-analysis is another related topic. However, the principle of meta-analysis is different from the 
proposed approach which address genetic basis of combinations of diseases/traits. In a meta-analysis, we 
aggregate evidence from different studies of the same or highly related traits to improve power; if one variant 
is highly significant in one large study, the final meta-analysis result will likely still be significant, regardless 
of the results of other studies. In addition, meta-analyses are not designed for finding genetic variants for a 
disease without a comorbid condition, such as DM with no overweight/obesity16 . 
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Method 
 
    In this study we introduce a statistical framework which has the potential to uncover susceptibility loci for 
comorbid disorders (or a disorder without comorbidity). It allows one to approximate the GWAS statistics for 
a comorbidity or a single disorder without comorbid trait based on the GWAS summary statistics of 
corresponding disorders only. 
 
    Here, we start by providing the derivation of GWAS summary statistics of interested trait (either a 
comorbid disorder or only single disorder without comorbidity) based on individual summary statistics. 
Suppose 𝑃ଵ and  𝑃ଶ are two different binary clinical traits. The interested clinical trait 𝑇 = 𝑓(𝑃ଵ, 𝑃ଶ) can be 
defined as a function of the corresponding phenotypes. Let 𝑆 ~ 𝑏𝑖𝑛(𝑛 = 2, 𝑞)  be a binomially distributed 
variable corresponding to the number of effect alleles(EA) of a biallelic SNP, where 𝑞 denotes the effect allele 
frequency. Suppose we have a multivariate linear regression model on a data set of size 𝑁, then we have: 
൦
𝑃ଵଵ
𝑃ଵଵ
⋮
𝑃ଶଵ
𝑃ଶଶ
⋮
𝑃ଵே 𝑃ଶே
൪ = ൦
1
1
⋮
𝑆ଵ
𝑆ଶ
⋮
1 𝑆ே
൪ ൤𝛽଴ଵ 𝛽଴ଶ𝛽ଵଵ 𝛽ଵଶ
൨ +  𝜖 2.1 
where 𝑃 is a 𝑁 ×  2 matrix, 𝑆 is a 𝑁 ×  2 matrix, 𝛽 is a 2 × 2 matrix, and 𝜖 is a 𝑁 ×  2 matrix. We assume 
each row 𝜖 is independent and follows a multivariate normal distribution 𝜖 ~𝛮(0, ∑). If we have known the 
estimate for the matrix 𝛽 (denoted by 𝛽መ), standard errors of each 𝛽ଵఫ෢ , the covariance matrix between 𝑃ଵ and  
𝑃ଶ, as well as the mean of these two phenotypes. This is equivalent to have the GWAS summary statistics of 
each phenotype and their phenotypic covariances. Our goal is to estimate 𝛾଴, 𝛾ଵ for the target trait(either a 
comorbid disorder or only single disorder without comorbidity), i.e., 
𝑓(𝑃ଵ௜ , 𝑃ଶ௜) = : 𝑇௜ = 𝛾଴ + 𝛾ଵ𝑆௜ + 𝑒௜ 2.2 
where 𝑒௜ follows a normal distribution with zero mean. Obviously, it’s equivalent to perform a GWAS for 
trait 𝑇. To realize this, we use the second-order Taylor approximation of 𝑇 around the point 𝜖(𝑠) for 𝑠 =
0, 1, 2 where 𝜖(𝑠): = (𝐸[𝑃ଵ௜|𝑆௜ = 𝑠], [𝑃ଶ௜|𝑆௜ = 𝑠])). Here point 𝜖(𝑠) corresponds to the mean of the phenotypes of 
the individuals who has 𝑠 effect alleles on this SNP. The second-order Taylor approximation for the trait can 
be expressed as: 
𝐿௜ ∶= 𝑓൫𝜖(𝑠)൯ +  ෍
𝜕𝑓൫𝜖(𝑠)൯
𝜕𝑃௞
(𝑃௞௜ − 𝐸[𝑃௞௜|𝑆௜ = 𝑠]) +
1
2
෍ ෍
𝜕ଶ𝑓(𝜖(𝑠))
𝜕𝑃௟𝜕𝑃௞
(𝑃௟௜ − 𝐸[𝑃௟௜|𝑆௜ = 𝑠])(𝑃௞௜ − 𝐸[𝑃௞௜|𝑆௜ = 𝑠])
ଶ
௞ୀଵ
ଶ
௟ୀଵ
ଶ
௞ୀଵ
 2.3 
where 𝜕𝑓൫𝜖(𝑠)൯/ 𝜕𝑃௞  and  𝜕ଶ𝑓(𝜖(𝑠))/𝜕𝑃௟𝜕𝑃௞  denote the first- and second-order partial derivates of 𝑓  with 
respect to the corresponding phenotypes respectively, calculated at point 𝜖(𝑠). Based on the linearity of the 
expectation operation, we have 
𝐸[𝐿௜|𝑆௜ = 𝑠] = 𝐸ൣ𝑓൫𝜖(𝑠)൯ห𝑆௜ = 𝑠൧ + 𝐸 ൥
1
2
෍ ෍
𝜕ଶ𝑓൫𝜖(𝑠)൯
𝜕𝑃௟𝜕𝑃௞
(𝑃௟௜ − 𝐸[𝑃௟௜|𝑆௜ = 𝑠])(𝑃௞௜ − 𝐸[𝑃௞௜|𝑆௜ = 𝑠])|
ଶ
௞ୀଵ
ଶ
௟ୀଵ
𝑆௜ = 𝑠൩ 
                             = 𝑓൫𝜖(𝑠)൯ + ଵ
ଶ
𝑓"൫𝜖(𝑠)൯ 
2.4 
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     Notably, the linearization is possible only if it meets certain conditions on the phenotype value space. To 
be more specific, division by 0 is not allowed. We can avoid this situation by linear transformation of the 
observed phenotypes and parameters in the 𝛽  matrix. If we neglect the minor errors incurred during the 
linearization process, we will have  
𝐸[𝐿௜|𝑆௜ = 𝑠] =  𝐸[𝐶௜|𝑆௜ = 𝑠] =  𝛾଴ + 𝛾ଵ𝑠 2.5 
 
Then we will have a direct approximation for 𝛾଴ when 𝑠 = 0, i.e., 
𝛾଴ෝ =  𝑓(𝛽଴ଵ, 𝛽଴ଶ) +
1
2
𝑓"(𝛽଴ଵ, 𝛽଴ଶ) 2.6 
We can also estimate 𝛾ଵ by evaluate it for  𝑠 = 1, 2 and weighting the results by their relative population 
frequency, i.e., 
                                 𝛾ଵෝ  =  
ଶ௤(ଵି௤)
ଶ௤(ଵି௤)ା௤మ
ቀ𝑓(𝛽଴ଵ + 𝛽ଵଵ, 𝛽଴ଶ + 𝛽ଵଶ) +
ଵ
ଶ
𝑓"(𝛽଴ଵ + 𝛽ଵଵ, 𝛽଴ଶ + 𝛽ଵଶ) − 𝛾଴ෝ ቁ 
                                  + ௤
మ
ଶ௤(ଵି௤)ା௤మ
ቀ௙(ఉబభାଶఉభభ,ఉబమାଶఉభమ)ା
భ
మ௙
"(ఉబభାଶఉభభ,ఉబమାଶఉభమ)ିఊబෞቁ
ଶ
 
2.7 
Since we don’t have the covariance matrix of 𝛽መ , we need to estimate it between each of the 𝛽పఫ෢ .  Based on our 
multivariate linear regression assumption, the corresponding covariance matrix of 𝛽መ  can be given by: 
𝑉𝑎𝑟൫𝛽መ൯ =  (𝑆்𝑆)ିଵ⨂∑ 2.8 
where ∑  is a 2 ×  2  matrix with ∑௟௞ = 𝐶𝑜𝑣(𝜖௟, 𝜖௞) , which is the covariance between errors in the linear 
regression of phenotypes 𝑃௟ ,  𝑃௞  on SNP S. To get the covariance matrix, one needs to analyze all the 
phenotypes at the same time which is not desirable. Based on the suggestions given by the original authors, 
we can get an approximation of 𝑉𝑎𝑟൫𝛽መ൯ instead of analyzing all phenotypes. We assume each individual SNP 
has small effect on the corresponding phenotype, so 𝑉𝑎𝑟(𝜖௟) ≈ 𝑉𝑎𝑟(𝑃௟) and 𝐶𝑜𝑣(𝜖௟, 𝜖௞) ≈ 𝐶𝑜𝑣(𝑃௟ , 𝑃௞). Thus, we 
can infer 
𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯ ≈ 𝑆𝐸௟𝐶𝑜𝑟(𝑃௟ , 𝑃௞)𝑆𝐸௞ 2.9 
Notably, the above equation only holds for completely overlapped phenotypes. If there is only partial overlap, 
𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯ can be approximated as: 
𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯ = 𝑆𝐸௟𝐶𝑜𝑟(𝑃௟, 𝑃௞)
𝑁∩௟,௞
ඥ𝑁௟𝑁௞
𝑆𝐸௞ 2.10 
Where 𝑁௟ and 𝑁௞ are the number of individuals for the GWAS of 𝑃௟ and 𝑃௞ respectively, while 𝑁∩௟,௞ is the 
number of individuals both in the GWAS of 𝑃௟ and GWAS of 𝑃௞. If 𝐶𝑜𝑟(𝑃௟ , 𝑃௞) can’t be directly calculated, 
we can use LD score regression to estimate 𝐶𝑜𝑟(𝑃௟ , 𝑃௞)
ே∩೗,ೖ
ඥே೗ேೖ
 based on GWAS summary statistics. Notably, if 
there is no sample overlap between the phenotypes, then 𝑁∩௟,௞  is zero, so is the term 𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯. The 
covariance between intercepts 𝐶𝑜𝑣൫𝛽଴௟෢ , 𝛽଴௞෢ ൯ can be expressed as: 
𝐶𝑜𝑣൫𝛽଴௟෢ , 𝛽଴௞෢ ൯ = 𝐶𝑜𝑣൫𝑃௟ഥ − 𝑆̅𝛽ଵ௟෢ , 𝑃௞തതത − 𝑆̅𝛽ଵ௞෢ ൯ = 𝐶𝑜𝑣(𝑃௟ഥ , 𝑃௞തതത) − 𝑆̅𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝑃௞തതത൯ − 𝑆̅𝐶𝑜𝑣൫𝛽ଵ௞෢ , 𝑃௟ഥ ൯ + 𝑆̅ଶ𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯ 2.11 
 
Since 𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝑃௞തതത൯ is zero and 𝐶𝑜𝑣(𝑃௟ഥ , 𝑃௞തതത) is negligible when sample size is large (typical GWAS sample sizes 
are >10,000 or more), the above equation can be simplified as: 
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𝐶𝑜𝑣൫𝛽଴௟෢ , 𝛽଴௞෢ ൯ ≈  𝑆̅ଶ𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯ 2.12 
Similarly, we get  
𝐶𝑜𝑣൫𝛽଴௟෢ , 𝛽ଵ௞෢ ൯ =  𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽଴௞෢ ൯ = 𝑆̅𝐶𝑜𝑣൫𝛽ଵ௟෢ , 𝛽ଵ௞෢ ൯  
 
 
2.13 
A framework for application to binary phenotypes - uncovering the genetic basis of comorbid disorders 
or a single disorder without related comorbidity 
   The above derivations are based on continuous phenotypes. However, we are interested in disease traits 
which are usually binary. In this regard, we need to develop a framework to deal with binary phenotypes.  
 
Conversion of coefficient (from logistic model to that under a linear model and vice versa) 
In the above derivations it is assumed that we are dealing with coefficients obtained under a linear model. 
However, summary statistics for binary traits are usually derived from logistic regression. We therefore need 
to convert the coefficients from logistic models to those derived under linear models.   
Lloyd-Jones et al17 proposed a method for transforming summary statistics based on linear regression to 
odds ratio(𝑂𝑅ଵ): 
𝑂𝑅ଵ =  
[𝑘 + 𝛽ଵ(1 − 𝑝)][1 − 𝑘 + 𝛽ଵ𝑝]
[𝑘 − 𝛽ଵ𝑝][1 − 𝑘 − 𝛽ଵ(1 − 𝑝)]
 2.14 
where p indicates the effect allele frequency of the SNP under study 𝑆, 𝑘 represents the proportion of cases 
and β1 represents the coefficient under a linear model. This formula is useful for converting coefficients from 
a linear model to those under a logistic model and vice versa (see below). Note that the odds ratio [=exp(β)] 
estimate from a logistic regression is unbiased regardless of a retrospective or prospective design, with any 
level of over- or under-sampling of cases. This property however does not apply for linear regression18. To 
ensure that the final effect size estimate is close to the actual estimate when a prospective study is performed, 
we shall use the population lifetime risk estimate for k. Intuitively the analysis is performed as if we were 
doing a prospective study in the population.  In the final step we will convert the coefficient from a linear 
model back to a logistic coefficient, which we shall employ the lifetime time probability of the comorbidity 
[i.e. Pr(P1 and P2)] as input for k.  
As explained above, here we are also interested in the reverse of 2.14, i.e. solving for β1 (coefficient under a 
linear model) given the odds ratio (OR). Denoting the odds ratio (OR) of SNP 𝑆 regressed on the binary 
phenotype by α, we have  
(𝛼𝑘 − 𝑘)(1 − 𝑘) = 𝛽ଵଶ[𝑝(1 − 𝑝) + 𝛼𝑝(1 − 𝑝)] + 𝛽ଵ[𝛼𝑘(1 − 𝑝) + 𝛼𝑝 − 𝛼𝑝𝑘 + 𝑘𝑝 + (1 − 𝑝)(1 − 𝑘)] 2.15 
We could solve the above quadratic equation for β1. We choose the solution whose absolute value is smaller 
than the coefficient under a logistic model, i.e., 𝑎𝑏𝑠(𝛽ଵ) < 𝑎𝑏𝑠(log (𝛼)). This choice could be verified by 
experimenting with different k and randomly generated p from uniform distribution with value range of 
[0.05,0.95]. As demonstrated by Fig.S1, the absolute values of coefficient (β) for binary traits derived from a 
linear regression is smaller than the coefficient(𝛼) under a logistic model, i.e., 𝑎𝑏𝑠(𝛽) < 𝑎𝑏𝑠(log (𝛼)).  
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After the conversion, we may compute  𝛾଴ෞ and 𝛾ଵෝ . We can employ the delta method
19 to calculate the 
standard errors of 𝛾଴ෞ and 𝛾ଵෝ . In essence, the delta method can be used to quantify variance of a function based 
on its first-order Taylor approximation. Suppose 𝐺(𝑋) and  𝑈  are the transform functions and mean vector of 
random variables 𝑋 = (𝑥ଵ, 𝑥ଶ, … 𝑥௡). The first-order Taylor expansion approximation for the function can be 
written as: 
𝐺(𝑋) ≈ 𝐺(𝑈) + ∇𝐺(𝑈)் ∙ 𝐺(𝑋 − 𝑈) 2.16 
where ∇G(U) is the gradient of 𝐺(𝑋). Then, we can take the variance of this approximation as the estimation 
for the variance of 𝐺(𝑋), i.e., 
𝑉𝑎𝑟(𝐺(𝑋)) ≈ +∇𝐺(𝑈)் ∙ 𝐶𝑜𝑣(𝑋) ∙ ∇𝐺(𝑋) 2.17 
Covariance between the coefficients can be derived based on the methods described above.     
 
Modeling comorbid disorders or a disorder without comorbidity 
Let 𝑃ଵ and  𝑃ଶ be two different binary clinical traits (coded as 0 and 1 for the absence and presence of disease 
respectively), the presence of comorbidity (Comor) can be expressed as: 
𝐶𝑜𝑚𝑜𝑟 = 𝑓(𝑃ଵ, 𝑃ଶ) =  𝑃ଵ × 𝑃ଶ 2.18 
Thus we can infer the corresponding coefficient estimates as follows: 
𝐶𝑜𝑚𝑜𝑟(𝛾଴ෝ ) =  𝛽଴ଵ෢ × 𝛽଴ଶ෢ + 𝐶𝑜𝑣(𝑃ଵ, 𝑃ଶ) 2.19 
𝐶𝑜𝑚𝑜𝑟(𝛾ଵෝ ) =  
2𝑞(1 − 𝑞)
2𝑞(1 − 𝑞) + 𝑞ଶ
ቂቀ൫𝛽଴ଵ෢ + 𝛽ଵଵ෢ ൯ × ൫𝛽଴ଶ෢ + 𝛽ଵଶ෢ ൯ + 𝐶𝑜𝑣(𝑃ଵ, 𝑃ଶ)ቁ − 𝐶𝑜𝑚𝑜𝑟(𝛾଴ෝ )ቃ 
+
𝑞ଶ
2𝑞(1 − 𝑞) + 𝑞ଶ
ቂቀ൫𝛽଴ଵ෢ + 2𝛽ଵଵ෢ ൯ × ൫𝛽଴ଶ෢ + 2𝛽ଵଶ෢ ൯ + 𝐶𝑜𝑣(𝑃ଵ, 𝑃ଶ)ቁ − 𝐶𝑜𝑚𝑜𝑟(𝛾଴ෝ )ቃ
2
 
2.20 
 
Similarly, having a disorder (P1) but without a specific comorbidity (P2) (e.g. CAD without DM) can be 
expressed as: 
𝑆𝑖𝑛𝑔𝑙𝑒 = 𝑓(𝑃ଵ, 𝑃ଶ) =  𝑃ଵ × (1 − 𝑃ଶ) 2.21 
And the corresponding coefficient estimates can be estimated by: 
𝑆𝑖𝑛𝑔𝑙𝑒(𝛾଴ෝ ) =  𝛽଴ଵ෢ × (1 − 𝛽଴ଶ෢ ) − 𝐶𝑜𝑣(𝑃ଵ, 𝑃ଶ) 2.22 
𝑆𝑖𝑛𝑔𝑙𝑒(𝛾ଵෝ ) =  
2𝑞(1 − 𝑞)
2𝑞(1 − 𝑞) + 𝑞ଶ
ቂቀ൫𝛽଴ଵ෢ + 𝛽ଵଵ෢ ൯ × ൫1 − 𝛽଴ଶ෢ − 𝛽ଵଶ෢ ൯ − 𝐶𝑜𝑣(𝑃ଵ, 𝑃ଶ)ቁ − 𝑆𝑖𝑛𝑔𝑙𝑒(𝛾଴ෝ )ቃ 
+
𝑞ଶ
2𝑞(1 − 𝑞) + 𝑞ଶ
ቂቀ൫𝛽଴ଵ෢ + 2𝛽ଵଵ෢ ൯ × ൫1 − 𝛽଴ଶ෢ − 2𝛽ଵଶ෢ ൯ − 𝐶𝑜𝑣(𝑃ଵ, 𝑃ଶ)ቁ − 𝑆𝑖𝑛𝑔𝑙𝑒(𝛾଴ෝ )ቃ
2
 
2.23 
Note that cov(P1, P2) will cancel out in 2.20 and 2.23 hence this quantity does not affect the results.  
 
Extension to more than two traits 
   The above proposed framework could also be extended to more than two traits. The only difference is that 
one of inputs should be the summary statistics of the comorbidity instead of a single disease, which could be 
derived from our proposed framework. For example, if we are interested in the genetic architecture of CAD 
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comorbid with T2DM and obesity, we could estimate the summary statistics of CAD comorbid with T2DM 
first. Given the results, we could re-apply our methodology again to deal with comorbidity with the 3rd trait 
(obesity).  It is often difficult to extract the lifetime risk of more than 2 comorbid disorders from the literature. 
If this is the case, we could employ Mendelian randomization (MR) to infer the OR of comorbid 1st + 2nd trait 
on the third one first, then the overall lifetime risk can be computed based on the methodology described in a 
section below. In a similar vein, the proposed framework can be applied to an arbitrary number of traits by 
sequential application of our method.  
 
Application to clinically defined categories of quantitative traits 
    It also worth noting that our proposed framework is applicable to clinically defined categories of 
quantitative traits. For example, hyperlipidemia is a risk factor for many cardiovascular diseases and clinical 
thresholds for LDL-C, HDL-C and triglycerides have been defined to facilitate the identification and 
treatment for subjects at high risks. However, GWAS summary data are only available for lipids as a 
quantitative trait. One may wish to identify genetic variants contributing to for example comorbid CAD and 
hyperlipidemia, which is clinically important. To realize this, we need to transform coefficients derived from 
linear regression (with outcome as a continuous trait) (𝛽ଵ) to coefficients from logistic regression (with 
outcome as a binary trait, such as hyperlipidemia or not) (𝛽ଵ௕).  
Suppose 𝑆 ~ 𝑏𝑖𝑛(𝑛 = 2, 𝑞) is a binomially distributed SNP (where 𝑞 denotes the effect allele frequency,). 
For each continuous trait 𝑦, we may model the effects of each SNP by: 
𝑦 =  𝛽଴ + 𝛽ଵ𝑆 + 𝜀 2.29 
where  is an error term that follows a normal distribution. The variance of the error term can be given by : 
𝑉𝑎𝑟(𝜀) =  𝑉𝑎𝑟(𝑦) − 𝛽ଵଶ𝑉𝑎𝑟(𝑆) 2.30 
Since individual SNP usually contributes to a very small explained variance, the residual variance of 𝑦 given 
𝑆 is very close to the total variance of 𝑦. For each SNP 𝑆, we have: 
𝐸(𝑆) =  2𝑞(1 − 𝑞) + 2𝑞ଶ 2.31 
𝑉𝑎𝑟(𝑆) = 2𝑞(1 − 𝑞) 2.32 
Based on equation 2.29, we could compute the expected trait value for a given genotype, i.e., 
𝐸(𝑦|𝑆 = 0) =  𝛽଴ 2.33 
𝐸(𝑦|𝑆 = 1) =  𝛽଴ + 𝛽ଵ 2.34 
𝐸(𝑦|𝑆 = 2) =  𝛽଴ + 2𝛽ଵ 2.35 
Where 𝛽଴ can be calculated by : 
𝛽଴ = 𝐸(𝑦) − 𝛽ଵ 𝐸(𝑆) 
Given the genotype, the quantitative trait is assumed to follow a normal distribution. Since the mean [2.33 to 
2.35] and variance [2.30, or approximate by var(y)] of the normal distribution are both known, we can infer 
the probability that the trait value will exceed (or fall below) certain threshold(s).  
 
11 
 
    Then we could infer the corresponding odds for a clinically category (e.g. high LDL-C) for a given 
genotype, i.e., 𝑜𝑑𝑑𝑠ௌୀ଴ =
௉(௬|ௌୀ଴)
ଵି௉(௬|ௌୀ଴)
, 𝑜𝑑𝑑𝑠ௌୀଵ =
௉(௬|ௌୀଵ)
ଵି௉(௬|ௌୀଵ)
 and 𝑜𝑑𝑑𝑠ௌୀଶ =
௉(௬|ௌୀଶ)
ଵି௉(௬|ௌୀଶ)
. To estimate the 
coefficient 𝛽ଵ௕ when clinically defined categories of a quantitative trait are considered as the outcome, we 
could evaluate the above at 𝑆 = 1,2 and weigh them by their relative population frequency, i.e.,  
𝛽ଵ௕ =
2𝑞(1 − 𝑞)
2𝑞(1 − 𝑞) + 𝑞ଶ
log ൬
𝑜𝑑𝑑𝑠ௌୀଵ
𝑜𝑑𝑑𝑠ௌୀ଴
൰ +
𝑞ଶ
2𝑞(1 − 𝑞) + 𝑞ଶ
log ൬𝑜𝑑𝑑𝑠ௌୀଶ𝑜𝑑𝑑𝑠ௌୀ଴
൰
2
 2.39 
We may then use the delta method to calculate standard error of 𝛽ଵ௕.  
 
Computing probability of comorbidity P1 and P2 
    Our calculations require specifying the probability of comorbidity, 𝐸(𝑃ଵ𝑃ଶ),  for conversion of the linear 
coefficient back to the logistic scale in the final step of the algorithm. This measure is also required when the 
methodology is to be applied to three or more traits. While estimates could be obtained from related literature, 
the lifetime probability for comorbidity could be relatively hard to find.  
 
If this is the case, we can calculate it from the OR (or relative risk, RR) of trait 𝑃ଵ given the other trait 𝑃ଶ 
(in which P2 can be considered a risk factor). For example, one may obtain the OR of CAD given diabetes 
based on literature search or other means. Based on Bayes rule, we have: 
𝐸(𝑃ଵ𝑃ଶ) = Pr(𝑃ଵ = 1 𝑎𝑛𝑑 𝑃ଶ = 1) = Pr(𝑃ଵ = 1|𝑃ଶ = 1) × 𝑃𝑟(𝑃ଶ = 1) 2.25 
    Here we shall develop an approach to compute Pr(𝑃ଵ = 1|𝑃ଶ = 1) given OR or RR. Let fRF0 be the probability of 
having the disease (P1) given the absence of the risk factor (P2), fRF1 be the probability of having the disease 
(P1) given the presence of the risk factor (P2), PRF0 denote the probability of having no risk factor i.e. Pr(P2=0), 
and PRF1 denote the probability of having the risk factor i.e.  Pr(P2=1).  
From 2.25, we may also express 𝐸(𝑃ଵ𝑃ଶ)  as  fRF1 x PRF1.  
 
Note that we have 𝐾 =  𝑓 ୊଴𝑃ோி + 𝑓 ୊଴𝑅𝑅 ∙ 𝑃ோிଵ   or  
  𝑓 ୊଴ = 𝐾/(𝑃ோி଴ +  𝑅𝑅 ∙ 𝑃ோிଵ)      2.26 
When the RR of disease given the risk factor is available, the calculation is straightforward as by definition 
we have fRF1 = RR * fRF0 and  E(P1, P2) =  fRF1 x PRF1. The case is more complicated when only OR are 
available. Here we present an iterative procedure to estimate 𝐸(𝑃ଵ𝑃ଶ). In the first step we may use OR to 
approximate RR, 
 𝑓 ୊଴  ≈  𝐾/(𝑃ோி଴ +  𝑂𝑅 ∙ 𝑃ோிଵ) 2.27                        
From Zhang et al20 , OR may be estimated from RR by  
RR ≈ OR/(1 − 𝑓ோி଴ + 𝑓ோி଴ ∙ OR)   2.28                        
 
The newly estimated RR from 2.28 can be substituted back into 2.26 to obtain a new estimate of fRF0. The 
algorithm is iterated until RR becomes stable (change in RR between iterations <1e-10).  
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Finally we can compute the probability of comorbidity by E(P1, P2) =  fRF1 x PRF1. 
 
Simulation study  
Application to binary traits 
    To verify the feasibility and efficacy of our proposed framework, we simulated different sets of genotype-
phenotype data, with 300 SNPs (i.e. Nsnp = 300; coded as 0, 1, 2) and two binary traits. As the proposed 
framework is a SNP-based analysis, the number of simulated SNPs shall not affect the validity of our 
simulations. For each simulated SNP, the allele frequency was randomly generated from a uniform 
distribution with a value range of [0.05, 0.95]. The number of subjects with each disorder (i.e., 𝑛𝑐𝑎𝑠𝑒𝑠) was 
set to [10000, 20000, 50000, 100000] with a disease prevalence (𝐾) of 10%. Here, 𝑛𝑐𝑎𝑠𝑒𝑠 indicated the 
sample size of cases in the whole simulated population cohort. Sample size of the whole population (𝑛𝑡𝑜𝑡𝑎𝑙) 
was estimated by 𝑛𝑡𝑜𝑡𝑎𝑙 = ௡௖௔௦௘௦
௄
.  Then, based on the generated allele frequencies, we could infer the genetic 
profiles for the whole simulated population cohort. The total SNP-based heritability (ℎଶ) for each trait was set 
at 0.2 to 0.4, distributed among all SNPs. More specifically, we simulated standard normal variables zi ~ 
N(0,1), and set mean effect size µ =  ට ௛
మ
ேೞ೙೛
  . The actual effect size for SNPi was set at βi =µzi.  The total 
liability y equals the sum of effects from each SNP plus a residual (e), i.e. 𝑦 = ∑ 𝛽௜𝑥௜௜ + 𝑒; the total variance 
of y was set to one. Following the liability threshold model, subjects with total liability exceeding a certain 
threshold [= Φିଵ(𝐾), where K is the disease prevalence] are regarded as having the trait or disease. The non-
shared genetic covariance between the two traits was set to 0.1.   
 
  From the simulated population cohort, we simulated two case-control studies with traits A and B as the 
outcome respectively. Suppose the number of cases for trait A and B in the population are respectively 𝑁஺ and 
𝑁஻, and 𝑁 = 𝑚𝑎𝑥(𝑁஺, 𝑁஻). For trait A, we picked 𝑁஺ cases and  2𝑁 − 𝑁஺ controls from the population. As 
for trait B, we picked 𝑁஻  cases and  2𝑁 − 𝑁஻  controls from the population. For comparison, we also 
simulated a ‘real’ comorbidity GWAS by picking all the comorbid cases (𝑁௖௢௠௢௥) in the simulated population 
cohort who are identified as having both trait A and B. Then (2𝑁 − 𝑁௖௢௠௢௥) controls were included. Notably, 
case-control samples for two traits with different overlap rate () were simulated to demonstrate the feasibility 
of our proposed method. Here  was defined to be the ratio of overlapped samples (including overlapped 
cases 𝑁஺஻.௢௩௘௥௟௔௣  and controls 𝑁௖௧௥௟.௢௩௘௥௟௔௣) and all picked samples for each case-control study, i.e., 𝑃 =
 (𝑁஺஻.௢௩௘௥௟௔௣ + 𝑁௖௧௥௟.௢௩௘௥௟௔௣) 2𝑁⁄ . To adjust the overlap rate, we need to increase or decrease the number of 
common cases and/or controls for both traits. Two different overlap rates were simulated for both comorbid 
and single disorder. Notably, most shared subjects were controls as they were far more abundant than cases.   
 
    We also considered another type of study design, namely a prospective study of a population. The 
simulation scheme is similar to the above, except that the controls consisted of the rest of the population who 
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were not cases.  Again, we assessed the performance of our proposed method under different overlap rates.  
We first simulated completely overlapped cohorts for traits A and B. Then we simulated 50% overlapped 
cohorts, i.e., 50% cases and controls for trait B were from the cohort for trait A. Besides, we studied the 
performance of our proposed framework both for the case where all required parameters were given and for 
the case where disease prevalence was misspecified. 
 
Transforming regression coefficients for quantitative traits to those based on clinically meaningful categories    
    We simulated datasets to verify the feasibility of our proposed approach to ‘transform’ regression 
coefficients of quantitative traits to coefficients based on clinically defined categories.  The number of studied 
subjects for quantitative traits was set to [50000,100000]. For each simulated SNP, the allele frequency was 
randomly generated from a uniform distribution from [0.05,0.95]. SNP-heritability was set to 0.1 and 0.2. The 
aim was to compare the theoretical estimates of regression coefficients and SE (based on summary statistics 
alone) against those obtained from simulated raw genotype data.   
 
Application to binary traits in cardiovascular medicine 
     We applied our approach to 4 cardiometabolic disorders/traits, namely coronary artery disease21 (CAD), 
type 2 diabetes mellitus22 (T2DM), obesity23  (BMI>=30) and stroke24  (all types of stroke included), based 
on publicly available GWAS summary statistics. Details of these datasets are summarized in Table S1. Since 
the effect size of individual SNPs in different GWAS may not correspond to the same allele, we employed the 
‘harmonise_data’ function in the package TwoSampleMR (https://mrcieu.github.io/TwoSampleMR) which 
integrates GWAS summary statistics from different sources, taking into account DNA strand issues25-27. 
Analysis was performed for SNPs with MAF>=0.01. In total, we studied the genetic architectures of 18 
disease ‘subtypes’ (6 are comorbidities and the remaining 12 are ‘single’ diseases without relevant comorbid 
conditions) and identified contributing genetic variants.   
 
Genes, pathway and cell type enrichment analysis 
    To better understand the functional and biological mechanisms underlying the genetic component of these 
disease ‘subtypes’, we computed gene-based significance using MAGMA inserted in the web-based tool 
FUMA28,29 . We employed false discovery rate (FDR) for multiple testing correction and selected genes that 
with FDR<0.05 for further analysis. Also, we performed “tissue specificity” analysis by examining whether 
the susceptibility genes are differentially expressed in a particular tissue. Apart from these analyses, we also 
conducted pathway analysis using the program “ConsensusPathDB”, in order to unravel biological pathways 
that are unique to specific disease subtype and shared pathways among disease subtypes. Furthermore, we 
examined the cell types that are enriched for specific disease ‘subtypes’.  
 
Finding heritability explained by common variants 
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     To further understand the genetic architecture of the ‘subtypes’ of complex diseases, we calculated their 
SNP-based heritability by LD score regression (LDSR)30. We also explored the genetic correlation between 
different disease subtypes with LDSR. Our aim is clarify whether disease “subtypes” are genetically different 
from each other. 
 
Mendelian Randomization (MR) analysis  
Mendelian Randomization (MR) is a methodology for inferring the causal relationship between risk 
factors and outcomes, using genetic variants as ‘instruments’ to represent the exposure. Here we performed 
two-sample MR in which the instrument-exposure and instrument-outcome associations were estimated in 
different samples. MR was conducted with ‘inverse-variance weighted’ (MR-IVW)31 and Egger regression 
(MR-Egger)25  approaches. One of the concerns of MR is horizontal pleiotropy, in which the genetic 
instruments have effects on the outcome other than through effects on the exposure. Note that MR-Egger is 
able to give valid estimates of causal effects in the presence of imbalanced horizontal pleiotropy. It could be 
assessed by whether the Egger intercept is significantly different from zero.  
 
The IVW framework is widely used in MR. Here we used an IVW approach that is able to account for 
SNP correlations31. A similar approach may be used for MR-Egger, which allows an intercept term in the 
weighted regression. Please refer to25   and the Supplementary Text for details.  
Inclusion of a larger panel of SNPs in partial LD may enable higher variance to be explained, thus improving 
the power of MR27 . Including “redundant” SNPs in addition to the causal variant(s) would not invalidate the 
results. However, including too many variants with high correlations may result in unstable causal estimates27.  
 
To ensure the robustness of our findings, we performed MR at multiple r2 thresholds (0.001, 0.01, 0.05, 0.1 
and 0.15) and with SNP correlations taken into account. For simplicity, we mainly present the results at 
r2=0.05. However, as we shall present later, our findings are consistent across various thresholds and full 
results are given in supplementary table.  
 
Only SNPs which passed genome-wide significance (p<5E-8) were included as instruments. We employed 
the R packages “MendelianRandomization” (ver 0.4.1) and “TwoSampleMR” (ver 4.25) for analysis. If a SNP 
was not available in the outcome GWAS, we allow using a “proxy SNP” provided r2>=0.8 with the original 
SNP. LD was extracted from the 1000 Genomes European samples.  
 
Multiple testing correction 
    Multiple testing was corrected by the false discovery rate approach by Benjamini and Hochberg. The 
method controls the expected proportion false discoveries among the significant results.  
 
Results 
Simulation results  
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Simulation results for binary traits  
  Results of our simulation are presented in Tables 1 and 2. For more detailed simulation results, please refer 
to Table S2 and S3. The correlations between the estimated and actual coefficients were in general very high. 
Clearly, the correlation and RMSE improved with increased sample sizes and higher heritability explained by 
SNPs (i.e. with larger effect sizes of SNPs). Since current GWAS summary data are usually of very large 
sample sizes, often larger than 100,000, we believe the current method is sufficiently good to approximate the 
results from a GWAS of comorbid or other combination of diseases/traits. Also, the current method is valid 
under different rates of overlap between the input GWAS datasets. 
 
    In addition, it is obvious that the power increased with larger samples sizes (i.e., case sizes of 
corresponding traits) and heritability explained. The type I error is kept at or below 0.05 when results with 
p<=0.05 were considered significant. Interestingly, the power of the proposed analytic method is sometimes 
higher than the simulated actual GWAS with genotype data. This may be because only a small number of 
patients were affected with both diseases (Ncomor is low); on the other hand, the number of subjects affected 
with either disease is relatively larger, so the two sets of case-control GWAS data (of traits A and B) may 
contain more information than a GWAS on the minority who are affected by both diseases.  
 
Tables 3, 4 as well as S4 demonstrate the simulation results with misspecified population parameters for 
both comorbid and only single disorder. The proposed method is reasonably robust to misspecified population 
parameters.   
 
Table 1 Simulation results for comorbid disorders compared with “real” GWAS 
Overlap rate 
No. cases H2 A H2 B 
Correlation RMSE Inferred Real GWAS 
Beta SE Beta SE Power 
Type I  
Power 
Type I  
Cases Controls error error 
0.08 0.15 
10000 0.2 0.3 0.93095 0.90106 0.04914 0.02285 0.673 0.040 0.493 0.037 
20000 0.2 0.3 0.96271 0.90008 0.03921 0.01645 0.757 0.037 0.630 0.040 
50000 0.2 0.3 0.98470 0.90046 0.03131 0.01041 0.850 0.050 0.773 0.040 
100000 0.2 0.3 0.99084 0.90200 0.02732 0.00739 0.873 0.047 0.810 0.023 
10000 0.22 0.32 0.93668 0.88878 0.04894 0.02289 0.683 ------ 0.510 ------ 
20000 0.22 0.32 0.96226 0.89106 0.04029 0.01642 0.773 ------ 0.637 ------ 
50000 0.22 0.32 0.98538 0.89207 0.03249 0.01041 0.860 ------ 0.803 ------ 
100000 0.22 0.32 0.99034 0.89560 0.02912 0.00739 0.883 ------ 0.817 ------ 
0.04 0.4 
10000 0.2 0.3 0.91762 0.89548 0.05188 0.02079 0.637 0.037 0.493 0.040 
20000 0.2 0.3 0.96362 0.90304 0.04123 0.01511 0.770 0.030 0.627 0.033 
50000 0.2 0.3 0.97820 0.90767 0.03188 0.00953 0.820 0.047 0.767 0.047 
100000 0.2 0.3 0.98766 0.90933 0.02949 0.00682 0.870 0.047 0.827 0.027 
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10000 0.22 0.32 0.93242 0.90182 0.05058 0.02061 0.673 ------ 0.517 ------ 
20000 0.22 0.32 0.96264 0.88828 0.04169 0.01512 0.743 ------ 0.653 ------ 
50000 0.22 0.32 0.98104 0.89612 0.03339 0.00973 0.823 ------ 0.760 ------ 
100000 0.22 0.32 0.98962 0.89772 0.02875 0.00685 0.890 ------ 0.807 ------ 
Note: here No. cases indicates the number of cases we defined for our simulation scenarios, H2 indicates heritability, RMSE is 
abbreviated for root mean square error. Please refer to the main text for details on simulation methods. The ‘real’ GWAS was 
constructed by Ncomor cases and (2N- Ncomor) controls.  
 
 
Table 2 Simulation results for only single disorder compared with “real” GWAS 
Overlap rate 
No. cases H2 A H2 B 
Correlation RMSE Inferred Real GWAS 
Beta SE Beta SE Power 
Type I  
Power 
Type I  
Cases Controls error error 
0.13 0.15 
10000 0.2 0.3 0.95880 0.99865 0.02642 0.00027 0.617 0.043 0.583 0.030 
20000 0.2 0.3 0.96924 0.99862 0.02325 0.00027 0.740 0.040 0.760 0.050 
50000 0.2 0.3 0.98246 0.99881 0.01739 0.00018 0.823 0.040 0.807 0.040 
100000 0.2 0.3 0.98633 0.99884 0.01533 0.00011 0.870 0.050 0.890 0.043 
10000 0.22 0.32 0.96022 0.99843 0.02745 0.00030 0.657 ------ 0.600 ------ 
20000 0.22 0.32 0.97404 0.99853 0.02274 0.00028 0.743 ------ 0.760 ------ 
50000 0.22 0.32 0.98185 0.99874 0.01855 0.00019 0.830 ------ 0.840 ------ 
100000 0.22 0.32 0.98527 0.99872 0.01653 0.00012 0.873 ------ 0.880 ------ 
0.21 0.25 
10000 0.2 0.3 0.95253 0.99815 0.02809 0.00047 0.617 0.037 0.580 0.033 
20000 0.2 0.3 0.97124 0.99814 0.02271 0.00033 0.767 0.047 0.747 0.037 
50000 0.2 0.3 0.98356 0.99827 0.01646 0.00022 0.823 0.043 0.807 0.033 
100000 0.2 0.3 0.98407 0.99827 0.01645 0.00014 0.867 0.050 0.867 0.043 
10000 0.22 0.32 0.95888 0.99766 0.02761 0.00051 0.657 ------ 0.610 ------ 
20000 0.22 0.32 0.97158 0.99809 0.02323 0.00031 0.747 ------ 0.757 ------ 
50000 0.22 0.32 0.98096 0.99818 0.01860 0.00022 0.833 ------ 0.820 ------ 
100000 0.22 0.32 0.98517 0.99816 0.01657 0.00013 0.883 ------ 0.870 ------ 
Note: here No. cases indicates the number of cases we defined for our simulation scenarios, H2 indicates heritability, RMSE is 
abbreviated for root mean square error. 
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Table 3 Simulation results for comorbid disorders with misspecified population parameters 
Overlap rate 
No. Original  Misspecified  Correlations RMSE Power 
case 
Trait  Trait  Trait  Trait  
Beta SE Beta SE Inferred Real GWAS 
A B A B 
100% 
10000 0.1 0.1 0.12 0.1 0.94209 0.93944 0.04325 0.02057 0.673 0.52 
10000 0.1 0.1 0.14 0.1 0.94208 0.95796 0.04269 0.01647 0.673 0.52 
10000 0.1 0.1 0.16 0.1 0.94177 0.97031 0.04895 0.01242 0.673 0.52 
20000 0.1 0.1 0.12 0.1 0.96841 0.94076 0.03188 0.01435 0.75 0.58 
20000 0.1 0.1 0.14 0.1 0.96815 0.95834 0.03179 0.01142 0.753 0.58 
20000 0.1 0.1 0.16 0.1 0.96755 0.96978 0.04034 0.00852 0.76 0.58 
10000 0.1 0.1 0.12 0.12 0.94242 0.95852 0.04265 0.01624 0.67 0.52 
10000 0.1 0.1 0.14 0.14 0.94196 0.97601 0.06701 0.00597 0.67 0.52 
10000 0.1 0.1 0.16 0.16 0.93913 0.94061 0.11372 0.00913 0.67 0.52 
20000 0.1 0.1 0.12 0.12 0.96879 0.95814 0.03134 0.01141 0.743 0.58 
20000 0.1 0.1 0.14 0.14 0.96817 0.97504 0.05997 0.00414 0.743 0.58 
20000 0.1 0.1 0.16 0.16 0.96529 0.94451 0.10789 0.00629 0.743 0.58 
50% 
10000 0.1 0.1 0.12 0.1 0.93607 0.94281 0.04492 0.02695 0.760 0.520 
10000 0.1 0.1 0.14 0.1 0.93614 0.96006 0.04501 0.02386 0.757 0.520 
10000 0.1 0.1 0.16 0.1 0.93596 0.97124 0.05153 0.02080 0.753 0.520 
20000 0.1 0.1 0.12 0.1 0.96515 0.94271 0.03323 0.01909 0.820 0.580 
20000 0.1 0.1 0.14 0.1 0.96460 0.95924 0.03350 0.01689 0.827 0.580 
20000 0.1 0.1 0.16 0.1 0.96369 0.96917 0.04210 0.01472 0.823 0.580 
10000 0.1 0.1 0.12 0.12 0.92912 0.95839 0.04830 0.02415 0.740 0.513 
10000 0.1 0.1 0.14 0.14 0.92995 0.97785 0.06608 0.01647 0.740 0.513 
10000 0.1 0.1 0.16 0.16 0.92954 0.95283 0.10798 0.00831 0.740 0.513 
20000 0.1 0.1 0.12 0.12 0.96637 0.95929 0.03216 0.01682 0.803 0.613 
20000 0.1 0.1 0.14 0.14 0.96592 0.97127 0.05870 0.01133 0.803 0.613 
20000 0.1 0.1 0.16 0.16 0.96268 0.92721 0.10688 0.00583 0.803 0.613 
Note: RMSE is abbreviated for root mean square error. Here the simulation results are based on whole population studies, thus the 
overlap rate indicates the overlap between two simulated populations for two traits. Original indicates the real disease prevalence, 
Misspecified indicates the ones we used for the inference of the statistics for comorbid disorder. 
 
Table 4 Simulation results for only single disorder with misspecified population parameters 
Overlap  No. cases 
Original  Misspecified  Correlations RMSE Power 
Trait  Trait  Trait  Trait 
Beta SE Beta SE Inferred Real GWAS 
A B A B 
100% 
10000 0.1 0.1 0.12 0.1 0.99451 0.99427 0.02326 0.00323 0.667 0.647 
10000 0.1 0.1 0.14 0.1 0.99439 0.98758 0.03874 0.00668 0.667 0.647 
10000 0.1 0.1 0.16 0.1 0.99415 0.97807 0.05409 0.01002 0.667 0.647 
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20000 0.1 0.1 0.12 0.1 0.99634 0.99349 0.02298 0.00227 0.78 0.767 
20000 0.1 0.1 0.14 0.1 0.99603 0.98519 0.03907 0.00473 0.78 0.767 
20000 0.1 0.1 0.16 0.1 0.99548 0.9725 0.05498 0.00713 0.78 0.767 
10000 0.1 0.1 0.12 0.12 0.99551 0.99457 0.02079 0.00277 0.683 0.647 
10000 0.1 0.1 0.14 0.14 0.9956 0.98942 0.03335 0.00557 0.68 0.647 
10000 0.1 0.1 0.16 0.16 0.99455 0.98289 0.04549 0.00813 0.693 0.647 
20000 0.1 0.1 0.12 0.12 0.99746 0.9939 0.0204 0.00194 0.78 0.767 
20000 0.1 0.1 0.14 0.14 0.99753 0.98759 0.03356 0.00394 0.797 0.767 
20000 0.1 0.1 0.16 0.16 0.99639 0.97886 0.04619 0.00576 0.797 0.767 
50% 
10000 0.1 0.1 0.12 0.1 0.99551 0.99476 0.02198 0.00276 0.700 0.707 
10000 0.1 0.1 0.14 0.1 0.99540 0.98722 0.03787 0.00614 0.703 0.707 
10000 0.1 0.1 0.16 0.1 0.99510 0.97579 0.05373 0.00943 0.703 0.707 
20000 0.1 0.1 0.12 0.1 0.99671 0.99371 0.02297 0.00238 0.793 0.803 
20000 0.1 0.1 0.14 0.1 0.99655 0.98484 0.03937 0.00488 0.793 0.803 
20000 0.1 0.1 0.16 0.1 0.99610 0.97102 0.05566 0.00732 0.793 0.803 
10000 0.1 0.1 0.12 0.12 0.99626 0.99511 0.01970 0.00234 0.700 0.707 
10000 0.1 0.1 0.14 0.14 0.99622 0.98940 0.03277 0.00512 0.697 0.707 
10000 0.1 0.1 0.16 0.16 0.99512 0.98160 0.04543 0.00767 0.710 0.707 
20000 0.1 0.1 0.12 0.12 0.99768 0.99418 0.02046 0.00207 0.807 0.803 
20000 0.1 0.1 0.14 0.14 0.99780 0.98755 0.03387 0.00412 0.813 0.803 
20000 0.1 0.1 0.16 0.16 0.99671 0.97837 0.04678 0.00601 0.813 0.803 
Note: here the simulation results are based on whole population studies, thus the overlap rate indicates the overlap between two 
simulated populations for two traits. Original indicates the real disease prevalence, Misspecified indicates the ones we used for the 
inference of the statistics for only single disorder. 
 
Simulation results for clinically defined categories of quantitative trait  
     Table 5 demonstrates the simulation results for clinically defined categories of quantitative trait. Similar to 
binary traits, the correlation between estimated and actual coefficients are high. To be more specific, the 
correlation and RMSE improved with increased sample sizes and higher heritability explained by SNPs (i.e. 
with larger effect sizes of SNPs). Considering current summary data for continuous traits are usually of very 
large sizes, often larger than 100,000, our proposed method is sufficiently good to approximate the results of 
clinically defined categories from a GWAS of continuous traits. 
 
 
 
 
 
Table 5 Simulation results for clinically defined categories of a continuous trait 
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Sample 
size 
Case 
size H
2 
Correlation  RMSE Power Type I error   
Beta SE Beta SE Inferred Real GWAS Inferred 
Real 
GWAS 
50000 7635 0.1 0.96518 0.99905 0.01596 0.00701 0.657 0.497 0.023 0.033 
50000 10336 0.1 0.97356 0.99936 0.01385 0.00612 0.657 0.507 0.023 0.027 
50000 7719 0.2 0.98126 0.99825 0.01626 0.00707 0.783 0.627 0.023 0.033 
50000 10455 0.2 0.98782 0.99894 0.01255 0.00545 0.783 0.653 0.023 0.023 
100000 15789 0.1 0.98216 0.99909 0.01138 0.00503 0.727 0.607 0.043 0.030 
100000 21103 0.1 0.98572 0.99966 0.00993 0.00417 0.727 0.650 0.047 0.063 
100000 15773 0.2 0.99133 0.99825 0.01112 0.00503 0.817 0.727 0.043 0.030 
100000 21345 0.2 0.99227 0.99894 0.01003 0.00387 0.817 0.773 0.043 0.063 
Note: here Sample size indicates the sample size of our simulated dataset, Case size indicates number of cases based on our clinically 
defined categories, H2 indicates heritability, RMSE is abbreviated for root mean square error. 
 
 
Application to cardiovascular disorders/traits  
   The proposed framework was applied to 4 cardiovascular diseases/traits, the combination of which results in 
18 disease ‘subtypes’ (6 are comorbidities and the remaining 12 are ‘single’ diseases without relevant 
comorbid conditions). We estimated the effect size (in terms of odds ratio comparing subjects with the disease 
‘subtype’ versus those without) and the corresponding SE and p-values based on our presented analytic 
framework. Following the definition by the GWAS analytic platform FUMA, independent significant SNPs 
are defined as those that with p<5e-8 and are independent from each other at the default r2 threshold (r2=0.6). 
As for the definition of genomic loci, independent significant SNPs which are correlated with each other at r2 
≥ 0.1 are assigned to the same risk locus. Then independent significant SNPs which lie within 250 kb are 
merged into one genomic risk locus. As for the lifetime risk of these involved diseases, some of them were 
directly extracted from relevant literatures32-37, while the remaining were inferred from odds ratios (or relative 
risks) from relevant studies (see supplementary Table S5).   
 
Genes, cell type and pathway analysis 
    Here we report the analysis results for the 18 disease ‘subtypes’. In total, we identified 384 and 587 
genomic risk loci respectively for 6 comorbidities and 12 disease ‘subtypes’ without a relevant comorbid 
condition (Table 6, Fig.1 and Table S6). Here we take Type 2 DM and obesity and the combination of these 
two traits as example. As expected, some susceptibility genes were shared among disease ‘subtypes’. For 
instance, TCF7L2 and CDKAL1 38 are the top susceptibility genes for all 3 disease subtypes involving T2DM 
and obesity39 It is also worth noting that TCF7L240-42  and CDKAL143,44  are also among the top genes for all 
three disease subtypes involving CAD and T2DM, suggesting a more general role of these genes in the 
pathogenesis of various forms of cardiometabolic abnormalities. Some susceptibility genes were only 
identified in specific disease subtypes. For example, FTO was found to be implicated only in disease subtypes 
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that involved obesity, i.e., obesity with or without T2DM, but not T2DM without obesity. This finding is 
consistent with previous studies that FTO mainly contributes to diabetes through its effects on BMI45-47 . 
Interestingly, BDNF was among the top genes for obese DM. BDNF treatment has been shown to reduce 
weight gain and glucose level in animal models and was also associated with glucose metabolism in clinical 
studies48 . On the other hand, genes such as JAZF1, HMGA2, COBLL1, KCNJ11 and PPARG were ranked 
among the top for non-obese DM, indicating these genes may contribute to glucose dysregulation other than 
through effects on BMI/obesity.  Notably, KCNJ11 and PPARG are also drug targets for sulphonylureas and 
thiazolidinediones (known anti-DM medications); further studies on the mechanisms and clinical efficacy of 
these classes of drugs in non-obese DM subjects may be warranted. For details about the concordant and 
discordant genes among disease subtypes, please refer to Table S7.  
 
    In addition, we also performed pathway analysis through the tool ConsensusPathDB. The enriched 
pathways were summarized in Table S8. Similar to gene analysis, some enriched pathways were shared 
among different disease subtypes while others were unique to particular disease subtype. Taking the 3 disease 
subtypes involving CAD and T2DM as example, statin pharmacodynamics, transcriptional regulation by 
RUNX3, and Angiopoietin receptor Tie2-mediated signaling were significantly enriched in all three disease 
subtypes, suggesting a boarder role of these biological pathways across CVD. There were also pathways that 
were only significantly enriched in certain disease subtype. For example, amb2 Integrin signaling49 and 
chylomicron/plasma lipoprotein clearance50  were top-ranked for non-diabetic CAD. As another example, 
adipogenesis and MAPK cascade pathways were enriched in CAD comorbid with T2DM. Previous studies 
have implicated a role of MAPK cascade in the pathogenesis of cardiac diseases and diabetes51-53.   
 
By investigating the pathways enriched for each disease ‘subtype’, we hope to gain insight into biological 
mechanisms that are generally important across CV disorders, as well as more ‘specific’ mechanisms that may 
play a more salient role for certain disease combinations.  
 
    Next we also performed cell-type and tissue specificity analysis through FUMA. FUMA pre-computes a list 
of genes differentially expressed in different tissues (DEGs) from GTEx; input genes (significant genes from 
MAGMA analysis in GWAS) are then tested for enrichment for these DEGs.  This approach is simple but 
differential expression does not always suggest causal role of the tissue. We consider this as a hypothesis-
generating analysis. According to the tissue analysis results, coronary artery and aorta were the most 
significantly enriched tissues only for disease subtypes that involved CAD. Interestingly, for disease subtypes 
including obesity without CAD, obesity without stroke and non-obese T2DM, the most significantly enriched 
tissues includes brain tissues such as cerebellar hemisphere, cerebellum and frontal cortex (Fig. S2). While the 
results will require further experimental validation, the brain has been suggested to play a key role in the 
control of body fat content and glucose metabolism54,55.  
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Recently methods have been developed for cell-type enrichment analysis based on GWAS56 , as single-cell 
sequencing data becomes more widely available. However, we note that single-cell data to date are more 
abundant for the brain than for other tissue types. This part is considered more exploratory as not all cell types 
are available for analysis in FUMA. We shall focus on the enrichment results for several comorbidities (most 
other disease combinations did not return significant results) . To highlight a few interesting findings (Fig. S3), 
we found GABAergic neurons in the midbrain and prefrontal cortex to be the most enriched cell type for CAD 
with obesity. Interestingly, it has been reported that leptin exerts its anti-obesity effects mostly through 
GABAergic neurons in the brain57. GABA neurotransmission is also thought to play a role in appetite 
regulation58. On the other hand, GABA in the CNS may also regulate the sympathetic outflow to the coronary 
vasculature, causing a change in vascular resistance59. For CAD with T2DM, we also found enrichment of 
endothelial cells in the pancreas.   
 
Table 6  Genome-wide significant SNPs  and risk loci for studied disease subtypes 
Disease subtypes No.  of ind. Sig. SNPs No. risk loci 
CAD with T2DM 9695 173 
CAD without T2DM 2582 51 
T2DM without CAD 7727 129 
CAD with Obesity 599 22 
CAD without Obesity 446 31 
Obesity without CAD 314 17 
CAD with Stroke 1189 34 
CAD without Stroke 1871 33 
Stroke without CAD 271 5 
T2DM with Obesity 1744 69 
T2DM without Obesity 2911 92 
Obesity without T2DM 316 16 
T2DM with Stroke 2585 72 
T2DM without Stroke 12260 175 
Stroke without T2DM 247 14 
Obesity with Stroke 359 14 
Obesity without Stroke 412 18 
Stroke without Obesity 111 6 
Note: here No.  of ind. Sig. SNPs indicates number of independent significant SNPs 
 
Heritability explained and genetic correlation among subtypes 
     In order to uncover how much variance could be explained by all common variants in the GWAS panel, we 
calculated the SNP-based heritability of our studied disease combinations by LD score regression14. As 
22 
 
demonstrated in Table 6, almost all comorbid cardiometabolic traits are more heritable than only single traits 
(without a comorbid disorder)..  
 
We also assessed the genetic correlation between different disease ‘subtypes’ as defined by the presence or 
absence of comorbid conditions. The comparison results are summarized in Table 7. Interestingly, many pairs 
had weak or moderate genetic correlations, implying that they are possibly distinct biological subtypes of the 
disease. For example, comorbid CAD/T2DM only has a weak genetic correlation with non-diabetic CA (rg = 
0.111), indicating that they may be genetically and biologically distinct ‘subtypes’. Similarly, only a moderate 
correlation was observed between obese CAD and non-obese CAD (rg = 0.232). Furthermore, we compared 
the extent of overlap of significant genetic variants among different pairs of disease subtypes. As expected, 
the weaker the genetic correlation, the lesser the overlap of significant SNPs between disease subtypes.  
 
Genetic correlation and MR analysis  
To further explore the genetic overlap between the studied disease subtypes and other cardiometabolic 
conditions (mainly stroke/CAD), we analyzed their genetic correlations using LD score regression (LDSR) 
(Table S9). This is also clinically relevant as we are often interested in whether a certain combination of traits 
is a significant risk factor for a certain disease. For example, do obese DM and non-obese DM confer the 
same risk to CAD? The findings will have implications for management and prevention of CAD.  Here we 
performed LDSR and MR on several selected traits with higher clinical relevance. Table 8 shows the results 
from LDSR. For example, we observed that similar genetic correlation between obese and non-obese DM 
with CAD, suggesting the extent of genetic overlap with CAD are similar. On the other hand, the genetic 
correlation between obesity (without T2DM) per se and CAD is relatively weak (rg = 0.0797). As another 
example, while T2DM with obesity is moderately genetically correlated with stroke (rg = 0.2779), obesity 
without T2DM has no significant genetic correlation with stroke.   
 
    We then performed further MR analysis for selected pairs of traits to assess causal relationships between 
several disease subtypes and cardiovascular outcomes (Table 10 and S10). For simplicity, we primarily report 
the results at r2= 0.05, but most results are consistent across different r2 thresholds. When focusing on CAD as 
the outcome, we found that obese DM is casually related to increased risk of CAD (MR-IVW; OR= 1.24, 95% 
CI: 1.16 to 1.33, p = 2.62E-11, Egger intercept p=0.355). Since we are studying binary exposures, the above 
OR roughly reflects the effect size with 2.72-fold increase in the exposure prevalence. Alternatively, the 
estimate may be multiple by 0.693 to reflect the OR resulted from doubling the prevalence of exposure60, 
which is presented in our tables. Similar results were observed at other r2 thresholds and with MR-Egger. 
Interestingly, we observed that obesity without DM does not have a significant causal link with CAD risks. On 
the other hand, non-obese DM showed no evidence of causal association under MR-Egger, but results were 
significant with MR-IVW. The Egger intercepts were significant (p<0.05 at all r2 thresholds), suggesting that 
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there is imbalanced horizontal pleiotropy, and that results from MR-Egger are more likely valid. The above 
finding suggests that some genetic variants may affect both non-obese DM and CAD risks via different 
pathways, leading to association between the two traits but the link may not be causal.  
 
    When considering stroke as the outcome, most disease subtypes studied were significantly and casually 
related to increased stroke risks. An exception is obesity alone without CAD or DM, which did not show a 
causal relationship with stroke. It is also worthwhile to note that the effect size also differs across different 
risk factors. For example, CAD comorbid with DM confers a higher risk (OR~ 1.12 per doubling of exposure 
prevalence; r2 = 0.05) for stroke than DM without CAD (OR~ 1.03 per doubling of exposure prevalence) or 
CAD without DM (OR ~ 1.06 per doubling of exposure prevalence).  
 
Table 7 Heritability of 18 disease combinations from LD score regression on the observed scale  
Comorbidities Heritability Single Trait Heritability Single Trait Heritability 
CAD with T2DM 0.0747 (0.0035) CAD without T2DM 0.0232 (0.0017) T2DM without CAD 0.0525 (0.0033) 
CAD with Obesity 0.1562 (0.0071) CAD without Obesity 0.1014 (0.0069) Obesity without CAD 0.1168 (0.0059) 
CAD with Stroke 0.0424 (0.0028) CAD without Stroke 0.0365 (0.0027) Stroke without CAD 0.0126 (0.0018) 
T2DM with Obesity 0.0681 (0.0027) T2DM without Obesity 0.0421 (0.0032) Obesity without T2DM 0.0241 (0.0014) 
T2DM with Stroke 0.0296 (0.0016) T2DM without Stroke 0.0568 (0.003) Stroke without T2DM 0.0077 (0.0009) 
Obesity with Stroke 0.0511 (0.0027) Obesity without Stroke 0.0574 (0.0028) Stroke without Obesity 0.0221 (0.0022) 
 
Table 8 Genetic correlation of different disease subtypes 
Subtype 1 Subtype 2 rg P No. overlapped sig. SNPs 
T2DM with Obesity T2DM without Obesity 0.667 8.304E-170 335 
T2DM with Obesity Obesity without T2DM 0.5568 6.059E-108 290 
CAD with T2DM CAD without T2DM 0.111 0.0044 638 
CAD with T2DM T2DM without CAD 0.6888 6.12E-198 3333 
CAD with Obesity CAD without Obesity 0.2324 7.11E-12 115 
CAD with Obesity Obesity without CAD 0.5686 2.13E-158 274 
CAD with Stroke CAD without Stroke 0.9802 2.38E-153 325 
CAD with Stroke Stroke without CAD 0.3756 2.03E-12 117 
T2DM with Stroke T2DM without Stroke 0.9348 0.00E+00 1845 
T2DM with Stroke Stroke without T2DM 0.1343 1.57E-02 172 
Obesity with Stroke Obesity without Stroke 0.6711 4.36E-306 282 
Obesity with Stroke Stroke without Obesity 0.4096 7.6493E-21 9 
Note: here rg indicates the genetic correlation between two traits. No. overlapped sig. SNPs indicates the number of SNPs with P < 
5E-8 in both disease subtypes. 
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Table 9  Genetic correlations between studies disease subtypes and other cardiometabolic conditions 
Disease subtypes  Conditions rg gcov P 
T2DM with Obesity CAD 0.357 0.0254 2.5714E-46 
T2DM without Obesity CAD 0.347  0.016 3.2467e-30  
Obesity without T2DM CAD 0.0797  0.007 0.0241  
CAD with T2DM Stroke 0.4737 0.0537 9.1061E-39 
CAD without T2DM Stroke 0.2941 0.0018 6.4598E-09 
T2DM without CAD Stroke 0.1368 0.0328 0.0005 
T2DM with Obesity Stroke 0.2779 0.0303 1.0613E-15 
T2DM without Obesity Stroke 0.3103  0.028 1.6109E-11  
Obesity without T2DM Stroke 0.0339  0.0256 0.502  
CAD with Obesity Stroke 0.3595 0.0201 1.509E-18 
CAD without Obesity Stroke 0.3585 0.0093 1.45E-11 
Obesity without CAD Stroke -0.0126 0.0061 0.7892 
Note: here rg indicates the genetic correlation between two traits, gcov indicates the intercept for genetic covariance calculation. 
Table 10  MR analysis results of selected pairs of traits. 
Exposure Outcome Estimate CILower CIUpper Pvalue Method 
T2DM without Obesity CAD  1.43E 03 -6.61E-02 6.32E-02 9.65E-01 Egger 
CAD with T2DM Stroke 1.64E 01 1.29E-01 1.98E-01 3.36E-20 IVW 
T2DM with Obesity CAD 2.21E 01 1.56E-01 2.87E-01 2.62E-11 IVW 
T2DM without Obesity Stroke 7.77E 02 4.83E-02 1.07E-01 2.32E-07 IVW 
T2DM without CAD Stroke 4.63E 02 2.29E-02 6.97E-02 1.06E-04 IVW 
CAD without Obesity Stroke 1.20E 01 5.03E-02 1.90E-01 7.59E-04 IVW 
CAD with Obesity Stroke 1.02E 01 3.95E-02 1.65E-01 1.43E-03 IVW 
T2DM with Obesity Stroke 9.99E 02 3.63E-02 1.63E-01 2.07E-03 IVW 
CAD without T2DM Stroke 8.16E 02 2.15E-02 1.42E-01 7.82E-03 IVW 
Obesity without T2DM CAD 7.46E 02 -2.96E-02 1.79E-01 1.60E-01 IVW 
Obesity without CAD Stroke 3.39E 02 -1.85E-02 8.64E-02 2.05E-01 IVW 
Obesity without T2DM Stroke 3.99E 03 -6.27E-02 7.07E-02 9.07E-01 IVW 
Note: here CILower indicates the lower bound for the confidence interval, CIUpper indicates the upper bound for the confidence 
interval.  
If the Egger intercept p-value was <0.05, the Egger regression approach was used; otherwise we employed the MR-IVW approach 
which has better statistical power.  
 
Extension to more than two traits 
As discussed above, our analytic framework may also be applied to the combination of three or more traits. 
To illustrate the methodology, we applied it to three cardiometabolic disorders, namely CAD, T2DM and 
obesity. Specifically, we explored the genetic architecture of obese T2DM comorbid with CAD, and non-
obese T2DM with CAD. In brief, we applied the analytic method sequentially by first deriving the GWAS 
results of DM with and without obesity, then adding CAD as input in the next step.  
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Accordingly, we identified 76 and 91 genomic risk loci respectively for obese T2DM with CAD and 
non-obese T2DM with CAD that exceed genome-wide significance (Table S6). Details about gene and 
pathway analysis results were summarized in Table S7 and S8. Similar to our results above, many 
susceptibility genes and enriched pathways were implicated in relevant pathophysiological process for the 
involved cardiometabolic diseases, and some genes/pathways are shared between the subtypes while some are 
top-ranked for specific subtypes. For a brief highlight of the results, for example, TCF7L2 and CDKN2B were 
among the top susceptible genes for both disease subtypes, while BDNF and HMGA2 were only found to be 
susceptible in obese T2DM+CAD and non-obese T2DM+CAD respectively. As for pathways, plasma 
lipoprotein assembly, remodeling and clearance was one of the top enriched pathways unique to obese T2DM 
with CAD while anti-diabetic drug potassium channel inhibitors pathway was only found to be significantly 
enriched in the other disease subtype, i.e., non-obese T2DM with CAD. 
 
Application to clinically defined categories 
     Furthermore, we applied our proposed framework to low-density lipoprotein cholesterol (LDL) based on 
publicly available summary statistics with a sample size of 188,57761 . Typically, a  LDL cholesterol level 
reading of 190 mg/dL or higher is considered as very high in clinical practice. Following this standard, we 
transformed the summary statistics of quantitative trait into that of binary trait. Then, we uncovered the 
genetic architectures of disease combinations involved CAD and high LDL utilizing our proposed framework. 
Totally, we identified 80, 40 and 65 genomic risk loci that exceed genome-wide significance respectively for 
CAD with high LDL, CAD without high LDL and high LDL without CAD. For details about these genomic 
risk loci, please refer to Table S6. Genes and pathways analysis results were demonstrated in Table S7 and S8. 
Analysis results suggest that identified susceptible genes and enriched pathways were strongly linked to the 
pathophysiology of involved disorders62-64. As for tissue specificity analysis, we found that liver was the most 
significantly enriched tissue for CAD with high LDL. 
 
Discussion  
Here we have presented a statistical framework to uncover susceptibility variants for combination of 
diseases/traits, based on summary statistics alone. The method is useful for revealing the genetic basis of 
comorbid disorders, or a disorder without comorbidity. More broadly speaking, the cases can be considered as 
those affected by as specific ‘subtype’ of the disease (as characterized by the presence or absence of comorbid 
traits). We also extended the methodology to deal with continuous traits with clinically meaningful categories 
(e.g. lipid levels), and to more than 2 traits.  
 
   There are several strengths and potential applications of the proposed framework. Firstly, as the method 
only requires GWAS summary statistics, our framework can be potentially applied to a large variety of 
complex diseases. This approach is likely more cost-effective than recruiting subjects with comorbid disorders. 
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As GWAS summary statistics with large sample sizes have dramatically increased these years, we believe the 
proposed framework represents a new paradigm and will open up countless opportunities to study the genetic 
basis and architecture of disease combinations. Such efforts will help shed light on heterogeneity and 
pathophysiology of different complex disorders, and may contribute to the identification of new drug targets 
and more personalized therapies. As for other clinical implications, different ‘subtypes’ of a disease may be 
related to different complications. For example, we found that obese DM is causally related to increased risks 
of CAD, but obesity without DM is not significantly linked to CAD. Similarly, LDSR also showed a weak 
genetic correlation between obesity with no DM and CAD. These analyses will help to refine causal risk 
factors for diseases and the formulation of prevention strategies. Note that other secondary analysis of GWAS 
summary data, such as transcriptome-wide association studies (TWAS), Summary-data-based Mendelian 
Randomization (SMR; based on eQTLs, methylation QTLs etc.), other SNP-based (partitioned) heritability 
estimation, pathway analysis approaches etc. may also be applied although we only illustrate the application 
of a few methods.  
   
  There are a few limitations to the current study. Similar to other methodologies that employ summary 
statistics from more than one sample, such as two-sample MR, there is an implicit assumption that both sets of 
summary statistics (assuming the study of 2 traits) are based on the same population. Large heterogeneity 
between the samples (e.g. different ethnic groups, large differences in inclusion/exclusion criteria etc.) may 
lead to inaccurate results. Also, most available summary statistics to date, including those we included in this 
study, are based on European samples. The results may not be transferable to other populations and it remains 
an open question how to accommodate summary data from different populations. While we believe the 
proposed framework is flexible and cost-effective, it could not completely replace the need to recruit subjects 
with comorbidities (or diseases without comorbidity). As discussed above, heterogeneity between study 
samples is inevitable, and recruitment of a more homogeneous sample with detailed phenotyping is still very 
valuable in uncovering the genetic basis of combination of diseases. While we highlights several genes and 
pathways underlying cardiometabolic traits, further experimental studies are required to validate the findings.  
 
  Taken together, we believe the proposed approach is a useful extension to conventional single-trait analysis. 
Identification of genetic variants for comorbid disorders or disease ‘subtypes’ may ultimately lead to more 
targeted prevention and treatment, and identification of novel drug targets.  
 
Supplementary Materials are available at 
https://drive.google.com/open?id=1Q_FGQIslb5MY6pOx6_5lXy3Gi8CgQL2s  
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Table S1 Details about the datasets for GWAS summary statistics inference after quality control 
 
Disease combination No. SNPs 
Sample size of the 1st disease Sample size of the 2nd disease 
Cases controls Cases controls 
CAD with T2DM 7,720,471 10,801 137,914 74,124 824,006 
CAD with Obesity 2,274,450 10,801 137,914 32,858 65,839 
CAD with Stroke 7,612,115 10,801 137,914 67,162 454,450 
T2DM with Obesity 2,277,486 74,124 824,006 32,858 65,839 
T2DM with Stroke 7,431,694 74,124 824,006 67,162 454,450 
Obesity with Stroke 2,274,378 32,858 65,839 67,162 454,450 
CAD without T2DM 7,720,471 10,801 137,914 74,124 824,006 
CAD without Obesity 2,274,450 10,801 137,914 32,858 65,839 
CAD without Stroke 7,612,115 10,801 137,914 67,162 454,450 
T2DM without Obesity 2,277,486 74,124 824,006 32,858 65,839 
T2DM without Stroke 7,431,694 74,124 824,006 67,162 454,450 
T2DM without CAD 7,720,471 74,124 824,006 10,801 137,914 
Obesity without CAD 2,274,450 32,858 65,839 10,801 137,914 
Obesity without T2DM 2,277,486 32,858 65,839 74,124 824,006 
Obesity without Stroke 2,274,378 32,858 65,839 67,162 454,450 
Stroke without CAD 7,612,115 67,162 454,450 10,801 137,914 
Stroke without T2DM 7,431,694 67,162 454,450 74,124 824,006 
Stroke without Obesity 2,274,378 67,162 454,450 32,858 65,839 
  
 
Table S2 Simulation results for comorbid disorders 
 
 
Table S3 Simulation results for single disorder without comorbidity 
 
 
Table S4 Simulation results for comorbid disorders and single disorders with misspecified population 
parameters 
 
 
 
Table S5  Odds ratios of involved diseases extracted from relevant studies 
 
Disorders OR 
CAD | Obesity 1.5 
CAD | Stroke 3.7 
T2DM | Obesity 9.4 
Stroke | Obesity 1.5 
 
 
 
 
Table S6   Identified susceptible genetic loci for studied disorders 
 
 
Table S7    Shared and unique genes among different disease “subtypes” based on MAGMA 
 
 
Table S8   Shared and unique pathways among different disease “subtypes” based on 
ConsensumPathDB 
 
 
Table S9    Genetic correlations between studied diseases and other diseases 
 
 
Table S10   MR analysis results for selected disorders 
 
Figure S1    Figure showing that the absolute values of coefficient for binary traits derived from a 
linear regression is smaller than the coefficient (𝛼) under a logistic model 
 
Figure S2   Results of tissue enrichment analysis  
 
Figure S3   Results of cell-type enrichment for comorbid disorders  
 
 
 
